A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)

Active, not recruitingOBSERVATIONAL

Enrollment

400

Participants

Timeline

Start Date

June 30, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Multiple Sclerosis

Interventions

DRUG

Natalizumab

Administered as specified in the treatment arm.

Trial Locations (1)

Research Site, Cambridge